

# PROGRAM

## 19<sup>th</sup> Annual Meeting of the ECNM Brno, Czechia

### Venue

**Best Western Premier  
Hotel International Brno  
Czech Republic**

### Organization


**Michael Doubek  
Jiří Mayer  
Peter Valent**

**August 26 – 28, 2021**


**[www.ecnm2021.eu](http://www.ecnm2021.eu)  
REGISTRATION**



**American  
Initiative in  
Mast Cell Diseases**



**ECNM**  
European Competence Network  
on Mastocytosis




# **Annual Meeting of the ECNM 2021** **Best Western Premier Hotel International** **Brno, Czech Republic**


**DAY 1 – Thursday, August 26, 2021**

- 11:00**      *Start of Registration*
- 12:00**      *Welcome Coffee*
- 13:00**      **Welcome Notes and Introduction**  
Michael Doubek and Jiri Mayer (Brno, Czech Republic)
- 13:15**      **Status of the ECNM in 2021 and Future Perspectives**  
Peter Valent (Vienna, Austria) & Massimo Triggiani (Salerno, Italy)
- 13:25**      **Presentation of the Researcher of the Year 2021**  
Massimo Triggiani (Salerno, Italy) & Peter Valent (Vienna, Austria)
- 13:30**      **Lecture of the Researcher of the Year 2021**  
**Development of Prognostication Models in Mastocytosis**  
Wolfgang R. Sperr (Vienna, Austria)
- 14:00**      *Coffee Break*
- 14:20**      **Session I: Diagnostic Evaluations in SM in 2021**  
Chairs: M. Triggiani & M. Arock
- 14:20**      **Histopathological Staging in Systemic Mastocytosis**  
Hans-Peter Horny (Munich, Germany)
- 14:40**      **Histologic Response Assessment in Advanced SM: Status 2021**  
Tracy George (Salt Lake City, UT, USA)
- 15:00**      **Flow Cytometry-Based Diagnosis and Response Evaluation in SM**  
Alberto Orfao (Salamanca, Spain)
- 15:20**      **Molecular Diagnostic Evaluations in Advanced SM**  
Gregor Hoermann (Munich, Germany)






- 15:40**      ***Coffee Break***
- 16:00**      **Session II: Prognostication in SM – Status 2021**  
**Chairs: C. Akin & A. Reiter**
- 16:00**      **Prognostic Factors and Patterns in Advanced SM: Status 2021**  
**Juliana Schwaab (Mannheim, Germany)**
- 16:20**      **International Prognostic Scoring System (IPSM)**  
**Wolfgang R. Sperr (Vienna, Austria)**
- 16:40**      **Global Prognostic Score for Mastocytosis (GPSM)**  
**Javier I. Muñoz-Gonzalez (Salamanca, Spain)**
- 17:00**      ***Coffee Break***
- 17:20**      **Session III: Mast Cell Activation, HAT and MCAS**  
**Chairs: H. Oude Elberink & D.D. Metcalfe**
- 17:20**      **Clinical Utility of Biomarkers of Mast Cell Activation**  
**Joseph H. Butterfield (Rochester, MN, USA)**
- 17:40**      **Hereditary Alpha-Tryptasemia (H $\alpha$ T): Molecular Mechanisms  
and Clinical Correlates**  
**Lawrence B. Schwartz (Richmond, MA USA)**
- 18:00**      **Evaluation of H $\alpha$ T in Patients with Mast Cell Neoplasms**  
**Georg Greiner (Vienna, Austria)**
- 18:20**      **Session IV: Classification and Management of MCAS**  
**Chairs: L.B. Schwartz & J.H. Butterfield**
- 18:20**      **Classification and Criteria of MCAS and Related Conditions**  
**Peter Valent (Vienna, Austria)**
- 18:40**      **Diagnosis and Management of Patients with MCAS**  
**Cem Akin (Ann Arbor, MI, USA)**
- 19:00**      **Summary of DAY 1 and Announcements**  
**Michael Doubek & Peter Valent**
- 20:00**      ***Dinner***




## **DAY 2 – Friday, August 27, 2021**

- 8:00**      ***Welcome Coffee***
- 8:25**      **Welcome & Introduction**  
**Peter Valent (Vienna, Austria)**
- 8:30**      **Session V: ECNM Registry Projects**  
**Chairs: W.R. Sperr & P. Valent**
- 8:30**      **Overview of Projects and Project Discussion**  
**Wolfgang R. Sperr (Vienna, Austria)**
- 8:50**      **Summary and Status of First Wave Projects**  
**Massimo Triggiani (Salerno, Italy) & Peter Valent (Vienna, Austria)**
- 9:10**      **Summary and Status of Second Wave Projects**  
**Peter Valent (Vienna, Austria) & Massimo Triggiani (Salerno, Italy)**
- 9:30**      ***Coffee Break***
- 10:00**      **Third Wave Projects**
- 10:00**      **Pure Cutaneous Mastocytosis in Adults (PR18)**  
**Knut Brockow (Munich, Germany)**
- 10:10**      **Subtypes of AHN: Course & Prognostic Features in Variants (PR19)**  
**Olivier Hermine (Paris, France)**
- 10:20**      **Bone Lesions and related Symptoms in Mastocytosis (PR20)**  
**Akif Selim Yavuz (Istanbul, Turkey)**
- 10:30**      **Prognostic Impact of the Percentage of Mast Cells in**  
**BM Smears versus BM Histologies (PR21)**  
**Vito Sabato (Antwerpen, Belgium)**
- 10:40**      **Diagnostic and Prognostic Impact of Cytogenetic Abnormalities (PR22)**  
**Dominique Bullens & Christine Breynaert (Leuven, Belgium)**
- 10:50**      **Prognostic Impact of Platelet Counts in SM (PR23)**  
**Deborah Christen & Jens Panse (Aachen, Germany)**
- 11:00**      ***Coffee Break***




- 11:30**      **Fourth-, Fifth-, Sixth and Seventh Wave Projects**
- 11:30**      **Pediatric Mastocytosis: Clinical Features and Course (PR29)**  
**Magdalena Lange & Marek Niedoszytko (Gdansk, Poland)**
- 11:40**      **Prognostic Impact of Monocytes in Mastocytosis (PR30)**  
**Friederike Wortmann & Nikolas von Bubnoff (Lübeck, Germany)**
- 11:50**      **Allogeneic SCT in Patients with Advanced SM (PR34)**  
**Khalid Shoumariyeh (Freiburg, Germany)**
- 12:00**      **Evaluation of Inflammation Parameters in Mastocytosis (PR31)**  
**Christos Fokoloros (Athens, Greece)**
- 12:10**      **Impact of Region and Referral Site Type (PR32)**  
**Knut Brockow (Munich, Germany)**
- 12:20**      **Impact of CD2, CD25, and CD30 Expression in MC in SM (PR36)**  
**Alex Rüfer (Luzern, Switzerland)**
- 12:30**      **Impact of Additional Mutations in ISM and SSM on OS and PFS (PR37)**  
**Michael Doubek (Brno, Czech Republic)**
- 12:40**      **Impact of Specific Allergies in Mastocytosis (PR38)**  
**Hanneke Oude Elberink (Groningen, The Netherlands)**
- 12:50**      **Additional Registry Projects, Summary and Discussion**  
**Peter Valent and ECNM Registry Group**
- 13:00**      ***Lunch Break***
- 14:00**      **Closed ECNM Registry Steering Committee Meeting**
- 15:00**      **Session VI: Cytoreductive and Targeted Therapy in SM**  
**Chairs: J. Gotlib & O. Hermine**
- 15:00**      **Preclinical Models to Determine Drug Effects in SM**  
**Michel Arock (Paris, France)**
- 15:20**      **Therapeutic Algorithms in Advanced SM: Update 2021**  
**Andreas Reiter (Mannheim, Germany)**




- 15:40**      **Evaluation of Avapritinib in Advanced SM: Status 2021**  
**Jason Gotlib (Stanford, CA, USA)**
- 16:00**      **Can we Offer KIT-Targeting TKI in ISM and SSM?**  
**Cem Akin (Ann Arbor, MI, USA)**
- 16:20**      ***Coffee Break***
- 17:00**      **Session VII: Criteria & Classification of SM: Recent Updates**  
**Chairs: H.P. Horny & K. Sotlar**
- 17:00**      **Course and Prognosis of Indolent Systemic Mastocytosis**  
**Michael Doubek (Brno, Czechia)**
- 17:20**      **Revised Diagnostic Criteria of Bone Marrow Mastocytosis**  
**Roberta Zanotti (Verona, Italy)**
- 17:40**      **Validation of CD30 as Minor Diagnostic Criterion of SM**  
**Iván Alvarez-Twose (Toledo, Spain)**
- 18:00**      **Key Note Lecture: Mast Cell Accumulation, Activation and Deficiency in the Mouse: Models and Perspectives**  
**Steven J. Galli (Stanford, CA, USA)**
- 18:30**      **Summary of DAY 2: Michael Doubek & Peter Valent**

### **DAY 3 – Saturday, August 28, 2021**

- 8:00**      ***Welcome Coffee***
- 8:15**      **Welcome & Introduction**  
**Peter Valent (Vienna, Austria)**
- 8:20**      **Session VIII: Cutaneous Involvement in Mastocytosis**  
**Chairs: M. Niedoszytko & M. Castells**
- 8:20**      **Novel Strategies and Technologies to Measure and Grade Cutaneous Involvement and Treatment Responses**  
**Karin Hartmann (Basel, Switzerland)**




- 8:40**      **New Therapeutic Approaches for the Treatment of Cutaneous Lesions and Skin Symptomatology in Mastocytosis**  
**Knut Brockow (Munich, Germany)**
- 9:00**      **Session IX: Pediatric Mastocytosis**  
**Chairs: K. Hartmann & K. Brockow**
- 9:20**      **Diagnosis and Prognostication in Pediatric Mastocytosis**  
**Magdalena Lange (Gdansk, Poland)**
- 9:40**      **Management and Therapy of Patients with Pediatric Mastocytosis**  
**Melody Carter (Bethesda, MD, USA)**
- 10:00**      ***Coffee Break***
- 10:40**      **Session IX: Anaphylaxis and MCAS**  
**Chairs: M. Carter & I. Alvarez-Twose**
- 10:40**      **IgE-Dependent Allergies and MCAS in SM Contexts**  
**Patrizia Bonadonna (Verona, Italy)**
- 11:00**      **Diagnosis and Therapy of Hymenoptera Venom Allergy in SM**  
**Marek Niedozytko (Gdansk, Poland)**
- 11:20**      **How to Separate MCAS from MCAS Mimickers**  
**Theo Gulen (Stockholm, Sweden)**
- 11:40**      **Key Note Lecture: Scientific Approaches to Measure Mast Cell Activation Patterns and Pathways**  
**Dean D. Metcalfe (Bethesda, MD, USA)**
- 12:10**      ***Lunch Break***
- 13:20**      **Session X: Co-Morbidities and Special Conditions**  
**Chairs: T. George & A. Orfao**
- 13:20**      **Spectrum of AHN in Various Organ Systems by Pathology**  
**Karl Sotlar (Salzburg, Austria)**
- 13:40**      **Skeletal and Neuronal Abnormalities in Patients with SM**  
**Olivier Hermine (Paris, France)**




- 14:00**      **Covid-19 Disease and Vaccination in Mastocytosis**  
**Mariana Castells (Boston, MA, USA)**
- 14:20**      **Allergies and Intolerance-Syndromes in Mastocytosis**  
**Hanneke Oude Elberink (Groningen, Netherlands)**
- 14:40**      ***Coffee Break***
- 15:00**      **Session XI: Eighth Late Breaking Abstracts (10+5 minutes)**  
**Chairs: P. Bonadonna & M. Doubek**
- 1.
  2. **NGS in systemic mastocytosis (J. Kotaskova, Brno, Czechia)**
  3. **Corona Receptor Expression on MC (L. Degenfeld, Vienna, Austria)**
  - 4.
  - 5.
  - 6.
  - 7.
  - 8.
- 17:00**      **Closing Remarks: Michael Doubek, Jiri Mayer & Peter Valent**





## Partners

---



## Sponsors

---

*Sponsors will be announced  
at the later date.*

**organizing agency**

---

**PROMCON**  
Creativity in Great Detail